Sum­mit shares rock­et up, fu­eled by an $842M pact with Duchenne leader Sarep­ta

With its mar­ket cap swelled by the FDA’s ap­proval of the con­tro­ver­sial Duchenne mus­cu­lar dy­s­tro­phy drug eteplirsen, Sarep­ta is now wheel­ing and deal­ing its way to new com­bi­na­tion ap­proach­es.

The Cam­bridge, MA-based biotech $SRPT has scored an $842 mil­lion deal to part­ner with Ox­ford, UK-based Sum­mit $SMMT Ther­a­peu­tics, bag­ging Eu­ro­pean-plus rights to a lead ther­a­py that fol­lows a com­ple­men­tary path­way to treat DMD.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER